Haselnuß Bencard Allergie

Haselnuß Bencard Allergie is a diagnostic allergen product containing hazelnut extract, intended for intraepidermal use in allergy testing. It is supplied without a specified strength or dosage form, and is marketed within the European Union. The preparation is used by healthcare professionals to assess sensitization to hazelnut in patients with suspected food allergy, supporting clinical decision‑making and to guide further management and appropriate dietary recommendations.

Haselnuß Bencard Allergie is employed primarily for in‑clinic diagnostic testing of hazelnut allergy.

- Screening patients with suspected hazelnut allergy. - Confirming sensitization after a positive skin prick test. - Supporting allergists in differentiating true allergy from tolerance. - Guiding dietary advice and avoidance strategies. - Assisting in research protocols involving hazelnut allergen exposure.

Side effects from intraepidermal hazelnut testing are generally mild, but clinicians should monitor for both common and rare reactions.

Common: - Local redness at the test site. - Mild swelling or papule formation. - Itching or transient discomfort. - Small wheal formation that resolves within 30 minutes.

Serious: - Systemic urticaria or hives. - Angioedema affecting lips, eyes, or airway. - Anaphylactic reaction requiring emergency treatment. - Severe bronchospasm or respiratory distress.

When using Haselnuß Bencard Allergie, healthcare providers should observe several precautions to ensure patient safety.

- Verify patient history for prior severe reactions to hazelnut. - Perform testing in a setting equipped for emergency management. - Use a standardized concentration and technique as recommended. - Observe the patient for at least 30 minutes after administration. - Document any adverse response and report serious events. - Avoid testing in patients on high‑dose antihistamines that may mask reactions.

Certain medications and conditions can influence the outcome of hazelnut allergen testing or increase risk of adverse events.

Avoid: - Beta‑blockers, which may worsen anaphylaxis management. - ACE inhibitors that can potentiate angioedema. - Recent systemic corticosteroid therapy that may suppress skin reactivity.

Use with caution: - Antihistamines, which may reduce test sensitivity; consider temporary discontinuation. - Immunotherapy targeting nut allergens, as it may alter skin test results. - Acute infections or dermatologic conditions at the test site.